To avoid anti-kickback litigation with government, pharma companies need a defensible position on FMV assessments
Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Articles by Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Latest Updated Articles
- Defending Fair Market Value (FMV) Assessments
Published: June 28th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
United States Delays Tariffs on Singapore’s Pharma Exports Amid Ongoing Trade Negotiations
3
Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site
4
How Healthcare Organizations Can Balance Federal and State AI Regulations
5
